NasdaqGM - Delayed Quote • USD
Ardelyx, Inc. (ARDX)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:51 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 8 |
| Avg. Estimate | -0.15 | -0.12 | -0.45 | 0.03 |
| Low Estimate | -0.25 | -0.2 | -0.76 | -0.44 |
| High Estimate | -0.12 | -0.09 | -0.2 | 0.4 |
| Year Ago EPS | -0.13 | -0.08 | -0.3 | -0.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 8 |
| Avg. Estimate | 35.81M | 46.97M | 207.25M | 362.41M |
| Low Estimate | 24.3M | 41.63M | 181.9M | 288.6M |
| High Estimate | 40M | 52.67M | 231.18M | 425.74M |
| Year Ago Sales | 11.37M | 15.27M | 124.46M | 207.25M |
| Sales Growth (year/est) | 215.00% | 207.60% | 66.50% | 74.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.1 | -0.11 | -0.11 | -0.09 |
| EPS Actual | -0.13 | -0.08 | 0.03 | -0.12 |
| Difference | -0.03 | 0.03 | 0.14 | -0.03 |
| Surprise % | -30.00% | 27.30% | 127.30% | -33.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.12 | -0.45 | 0.03 |
| 7 Days Ago | -0.14 | -0.12 | -0.44 | 0.03 |
| 30 Days Ago | -0.14 | -0.12 | -0.45 | 0 |
| 60 Days Ago | -0.1 | -0.07 | -0.22 | 0.23 |
| 90 Days Ago | -0.1 | -0.07 | -0.22 | 0.22 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | ARDX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -15.40% | -- | -- | 0.80% |
| Next Qtr. | -50.00% | -- | -- | 9.60% |
| Current Year | -50.00% | -- | -- | 4.50% |
| Next Year | 106.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 30.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Wedbush: Outperform to Outperform | 4/17/2024 |
| Initiated | Leerink Partners: Outperform | 4/5/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/23/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 2/23/2024 |
| Maintains | Wedbush: Outperform to Outperform | 1/12/2024 |
| Maintains | Citigroup: Buy to Buy | 1/10/2024 |
Related Tickers
AKBA Akebia Therapeutics, Inc.
1.3900
0.00%
CDTX Cidara Therapeutics, Inc.
0.7220
-0.03%
TGTX TG Therapeutics, Inc.
13.99
+1.23%
IOVA Iovance Biotherapeutics, Inc.
11.72
-0.68%
XFOR X4 Pharmaceuticals, Inc.
1.2000
+0.42%
PDSB PDS Biotechnology Corporation
2.9000
+6.62%
ALDX Aldeyra Therapeutics, Inc.
3.9800
+0.25%
MREO Mereo BioPharma Group plc
2.6500
+2.71%
MCRB Seres Therapeutics, Inc.
0.5842
-6.87%
HRTX Heron Therapeutics, Inc.
2.7100
-2.17%